Is focal therapy an alternative to active surveillance?

Journal of Endourology

Volumn 24, Issue 5, 2010, Pages 855-860

  Gravas, Stavros ^a   De Reijke, Theo ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SURVEILLANCE; ANXIETY; BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STATISTICS; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FOCAL THERAPY; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 77952556808     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2009.0525     Document Type: Review

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-990.
3. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
5. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792-1797.
6. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J Urol 2007;178:S14-S19.
7. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-2719.
8. Steineck G, Helgesen F, Adolfsson J, et al. Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-796.
9. Hoffman RM, Hunt WC, Gilliland FD, et al. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 2003;97:1653-1662.
10. Bastian PJ, Carter BH, Bjartell A, et al. Insignificant Prostate cancer and active surveillance: From definition to clinical implications. Eur Urol 2009;55:1321-1330.
11. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006;24:46-50. (Pubitemid 43097357)
12. Berglund RK, Masterson TA, Vora KC, et al. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance J Urol 2008;180: 1964-1967.
13. Louie-Johnsun M, Neill M, Treurnicht K, et al. Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically. BJU Int 2009;104: 1501-1504.
14. Martin RM, Gunnell D, Hamdy F, et al. Continuing controversy over monitoring men with localized prostate cancer: A systematic review of programs in the prostate specific antigen era. J Urol 2006;176:439-449.
15. Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for prostate cancer on surveillance. J Urol 2007;178:826-832.
16. Burnet KL, Parker C, Dearnaley D, et al. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 2007;100:540-543.
17. Arredondo SA, Downs TM, Lubeck DP, et al. Watchful waiting and health related quality of life for patients with localized prostate cancer: Data from CaPSURE. J Urol 2004;172:1830-1834.
18. Daubenmier JJ, Weidner G, Marlin R, et al. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. Urology 2006;67:125-130.
19. Bostwick DG, Waters DJ, Farley ER, et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006. Urology 2007;70(suppl 6):42-44.
20. Polascik TJ, Mayes JM, Mouraviev V. Nerve-sparing focal cryoablation of prostate cancer. Curr Opin Urol 2009;19: 182-187.
21. Mouraviev V, Mayes JM, Polascik TJ. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 2009;6:205-215.
22. Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: Review 2007. Urology 2007;70(suppl 6):3-8.
23. Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60:264-269.
24. Mouraviev V, Mayes JM, Sun L, et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007; 110:906-910.
25. Ohori M, Eastham JA, Koh H, et al. Is focal therapy reasonable in patients with early stage prostate cancer (CaP): An analysis of radical prostatectomy (RP) specimens. J Urol 2006;175(suppl):507. Abstract.
26. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers. J Urol 2003;170:459-463.
27. Eggener SE, Scardino PT, Carroll PR, et al. International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 2007;178:2260-2267.
28. Yoon GS, Wang W, Osunkoya AO, et al. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol 2008;179:2203-2206.
29. Eichler K, Hempel S, Wilby J, et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: A systematic review. J Urol 2006;175:1605-1612.
30. Scattoni V, Zlotta A, Montironi R, et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: A critical analysis of the literature. Eur Urol 2007;52:1309-1322.
31. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: The role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urology 2007;70(suppl 6):27-35.
32. Onik G, Barzell W. Transperineal 3D mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 2008;26:506-510.
33. Presti JC Jr, Hricak H, Narayan PA, et al. Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol 1996;166:103-108.
34. Quinn SF, Franzini DA, Demlow TA, et al. MR imaging of prostate cancer with an endorectal surface coil technique: correlation with whole-mount specimens. Radiology 1994;190:323-327.
35. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50:1163-1175.
36. Brame RS, Zaider M, Zakian KL, et al. Regarding the focal treatment of prostate cancer: Inference of the Gleason grade from magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2009;74:110-114.
37. Villers A, Lemaitre L, Haffner J, Puech P. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: Implications for focal therapy and active surveillance. Curr Opin Urol 2009;19:274-282.
38. Ahmed HU, Pendse D, Illing R, et al. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4:632-642.
39. Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176:2432-2437.